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Abstract 
Background. Anticoagulation control in patients with atrial fibrillation (AF) has a multidisciplinary approach 
although is usually managed by general practitioners (GP) or haematologists. The aim of our study was to 
assess the quality of anticoagulation control with vitamin K antagonists (VKAs) in relation to the responsible 
specialist in a “real‐world” AF population.  
Methods. We consecutively enrolled VKA anticoagulated patients included in the FANTASIIA Registry from 
2013 to 2015. We analysed demographical, clinical characteristics and the quality of anticoagulation control 
according to the specialist responsible (ie GPs or haematologists).  
Results. Data on 1584 patients were included (42.5% females, mean age 74.0 ± 9.4 years): 977 (61.7%) 
patients were controlled by GPs and 607 (38.3%) by haematologists. Patients managed by GPs had higher 
previous heart disease (53.2% vs 43.3%, P < .001), heart failure (32.9% vs 26.5%, P < .008) and dilated 
cardiomyopathy (15.2% vs 8.7%, P < .001) with better renal function (69.3 ± 24.7 vs 63.1 ± 21.4 mL/min, 
P < .001) compared to patients managed by haematologists. There was no difference between groups in the 
type of AF, CHA2DS2‐VASc or HAS‐BLED scores, but patients with electrical cardioversion were more 
prevalent in GP group. The overall mean time in therapeutic range (TTR) assessed by Rosendaal method was 
61.5 ± 24.9%; 52.6% of patients had TTR<65% and 60% of patients had TTR<70%. TTR was significantly 
lower in patients controlled by haematologists than by GPs (63 ± 24.4 vs 59.2 ± 25.6, P < .005).  
Conclusions. About 60% of AF patients anticoagulated with VKAs had poor anticoagulation control (ie 
TTR<70%), and their management was only slightly better than when it is managed by general practitioners.  
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1. INTRODUCTION 
Atrial fibrillation (AF) is the most common cardiac arrhythmia in developed countries
1-3
 and is 
associated with an increased mortality and morbidity rate, with an associated hospitalisation and 
healthcare costs.
2, 4-10
 Therefore, it is essential to ensure optimal and homogeneous management, 
with emphasis on quality of anticoagulation. Whilst well‐managed anticoagulation reduced stroke 
and mortality, poor anticoagulation control leads an increase in thrombotic and bleeding events, as 
well as mortality.
11 
 
Atrial fibrillation management is performed by various medical specialists, but anticoagulation 
control is usually managed by the general practitioner (GP) or haematologist and, in a smaller 
number of cases, by cardiologists or internists. To achieve a good control of the quality of 
anticoagulation requires experience and knowledge both by the doctor and the patient. Since 2010, 
we have seen annual updates of clinical practice guidelines (both European and American) 
containing new algorithms, use of thrombotic and bleeding risk scores, as well as the introduction 
of four nonvitamin K oral anticoagulants (NOACs), with a better safety profile. All these updates 
are useful, but their application in everyday clinical practice is not immediate. For that reason, the 
management of anticoagulation is not homogeneous among different professionals.  
 
On the other hand, the quality of anticoagulation control is not assessed in a homogeneous way 
by all groups. This assessment is sometimes the result of using a simple percentage of 
international normalised range (INR) in therapeutic range (PINRR)
12
 and, in other cases, by the 
time in the therapeutic range (TTR) as measured by the Rosendaal method.
13 
Although NOACs 
have emerged as an effective and safe alternative to VKA therapy, treatment with VKA is still a 
valid option in AF patients.
14
 The AuriculA registry from Swedish population showed that in 
patients who spend high proportion of time in the therapeutic range, the treatment with warfarin is 
safe and effective and will continue to be a valid option.
15 
 
The aim of our study was to assess the quality of anticoagulation control with vitamin K 
antagonists (VKAs) in relation to the responsible specialist in a “real‐world” AF population.  
2. METHODS 
2.1 Study design 
The data from this study come from the FANTASIIA Registry (“Fibrilación Auricular: 
influencia del Nivel y Tipo de Anticoagulación Sobre la incidencia de Ictus y Accidentes 
hemorrágicos”), a national, multicentric, observational and prospective study which main 
objective is to evaluate the incidence of thromboembolic and haemorrhagic events in a prospective 
sample of AF patients over 3 years of follow‐up, in relation to the type of antithrombotic agents, 
VKA or NOACs, and the quality of anticoagulation (in those who receive VKA). The design has 
been previously published
16
 and includes an initial visit and three follow‐up visits, after 1, 2 and 
3 years, where clinical and laboratory data of patients would be collected in an electronic data 
notebook. In this study, we assess the quality of anticoagulation control with VKAs in relation to 
the responsible specialist in a “real‐world” AF population: the GP or the haematologist.  
2.2 Study population 
A total of 1640 consecutive outpatients treated with VKAs were included in the analysis of this 
study. During the selection process, 56 patients were excluded because the data about the specialist 
in charge of their anticoagulation control were not available. Therefore, the final analysed sample 
size was 1584 patients.  
  
Demographic, clinical and analytical variables were collected from all patients in medical 
records. Previous major bleeding events were defined according to the 2005 International Society 
of Thrombosis and Haemostasis criteria: fatal bleeding or symptomatic bleeding in a critical 
anatomical site (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial or 
intramuscular with compartment syndrome) and/or bleeding causing a fall in haemoglobin ≥20 g/L 
or transfusion of ≥2 units of packed red blood cells. Patients with rheumatic mitral valvular disease 
or prosthetic valve patients were excluded.  
 
For the present analysis, two groups were established according to the specialist responsible of 
anticoagulation control: GPs or haematologists. In the first case, the control of anticoagulation was 
performed completely in the primary care centre, by GPs. The blood test was performed with a 
portable system, and the interpretation and adjustment of the pattern were established by the GPs. 
The way for the anticoagulation management option with GPs or haematologists depended of the 
geographical region of the patient (FANTASIIA registry is a multicenter registry that involves 50 
centres).  
 
In the case of haematology control, two modalities were observed according to the local care 
organisation: in the first, only the haematologist was responsible for the complete process of 
anticoagulation control; and in the second, a blood sample was extracted in the primary care 
centre, sent to the Hematology laboratory and the haematologist sent the recommendation of the 
anticoagulation treatment to the GPs who transmitted it to the patient.  
 
The FANTASIIA Registry complies with all the requirements of the Helsinki Declaration, and 
the study protocol was approved by the Clinical and Ethical Testing Committee of the Hospital 
Universitario San Juan de Alicante (approval number 12/220) by all Ethics Committees of the 
participating centres, as well as the Spanish Agency for Medicine and Health Products (SEC‐
ACO‐2012‐01 postauthorisation approval code). All the participating patients signed the informed 
consent. Reporting of the study conforms to STROBE statement along with references to 
STROBE statement and the broader EQUATOR guidelines.
17
 
2.3 Quality of anticoagulation control 
All available INR of each patient in the 6 months previous was collected at baseline with at 
least 1 INR per month to calculate the time in the therapeutic range. The FANTASIIA registry is 
an observational multicenter registry. For that reason, all the frequency of the INR determinations 
to maintain the INR between 2.0 and 3.0 and the frequency of visits to the physicians were 
performed following the usual clinical practice without any additional intervention. Poor quality of 
anticoagulation or “INR lability” was defined when patients experienced a TTR <65%. The TTR 
was estimated according to different methods. The main methodology employed was the classical 
linear method of Rosendaal.
13
 However, the quality of anticoagulation also was studied according 
to the direct method or percentage of INR in therapeutic range (PINRR). This method calculates 
the TTR according to the number of visits where the INR is in therapeutic range (between 2.0 and 
3.0) and divides it by the total number of visits. Similarly, the INR variability was estimated using 
the Fihn method,
18
 evaluating the INR variability using the growth rate of the variance according 
to the Fihn method. We assessed the quality of anticoagulation therapy following the ESC criteria 
of the percentage of patients with TTR <70% measured by Rosendaal.  
2.4 Statistical analysis 
Quantitative variables are described by mean and standard deviation or median and 
interquartile range based on whether they followed a normal distribution. To test the normal 
distribution, the Kolmogorov‐Smirnov test was used. For comparisons among groups, Student's t 
test was used in the case of continuous variables and Chi‐square in the case of qualitative 
variables, considering the value of P < .05 as statistically significant. We performed a logistic 
regression analysis to perform the univariate adjustment considering the clinical variables that 
have been demonstrated a relevant association with poor quality of anticoagulation (age, sex, 
hypertension, diabetes mellitus, previous bleeding, heart disease, Charlson index, CHADS2, 
CHA2DS2‐VASc, HAS‐BLED and specialist responsible of anticoagulation control). A 
multivariate logistic regression analysis was carried out with those of the relevant variables 
included in the univariate with a value of P < .150. The results are presented as odds ratio (OR) 
with a 95% confidence interval. STATA statistical version 12.0 was employed for the statistical 
analysis.  
3. RESULTS 
3.1 Comparison of baseline characteristics of both groups 
Of the 1,584 patients analysed, in 977 (61.7%) had anticoagulation management by GPs and in 
607 (38.3%) by haematologists. The mean age was 74.0 ± 9.4 years and 57.3% were male, with no 
significant differences between groups (Table 1). Comorbidities, risk factors, history of stroke and 
major haemorrhage appeared similar in both groups, although history of gastrointestinal 
haemorrhage was higher (3.7% vs 22.7%, P = .043) in the group managed by haematologists. All 
investigations, diagnoses and initial treatments data were similar in both groups. Mean glomerular 
filtration rate (63.1 ± 21.4 vs 69.4 ± 24.7 mL/min, P < .001) and the left ventricular ejection 
fraction (57.7 ± 11.8% vs 59.3 ± 10.6%, P = .040) were marginally better in the group managed by 
haematologists. More concomitant use of antiplatelet agents (12.5% vs 9.0%, P = .026) was 
observed in the group managed by haematologists.  
Table 1. Distribution of baseline clinical characteristics according to the specialist responsible of the anticoagulation 
control 
 
Total 
n = 1584 
General practitioner 
n = 977 
Haematologist 
n = 607 
P‐value 
 
Demographic 
Male sex 909 (57.3) 558 (57.1) 352 (58.0) .945 
Age (y) 74.0 ± 9.4 73.9 ± 9.6 74.2 ± 9.1 .945 
Comorbidities 
Hypertension 1,281 (80.9) 782 (80.0) 499 (82.2) .286 
Diabetes mellitus 478 (30.2) 292 (29.9) 187 (30.8) .698 
Dyslipidaemia 851 (53.7) 526 (53.8) 325 (53.5) .908 
Current smoker 81 (5.1) 54 (5.5) 26 (4.3) .272 
Current alcohol 57 (3.6) 35 (3.6) 22 (3.6) .965 
Any heart disease 782 (49.4) 520 (53.2) 263 (43.3) <.001 
COPD 284 (17.9) 189 (19.3) 94 (15.5) .051 
Previous stroke 250 (15.8) 152 (15.6) 98 (16.1) .755 
Extracranial embolism 32 (2.0) 21 (2.1) 12 (2.0) .923 
Malignant disease 150 (9.2) 93 (9.5) 52 (8.6) .523 
PAD 97 (6.1) 64 (6.6) 31 (5.1) .210 
Charlson Index 1.2 ± 1.2 1.2 ± 1.2 1.2 ± 1.1 .087 
Chronic kidney disease 
(eGFR ≤ 60 mL/min) 
335 (21.2) 221 (22.6) 114 (18.8) .069 
Hepatic disease 22 (1.4) 17 (1.7) 5 (0.8) .130 
Previous bleeding events 
Major bleeding 55 (3.1) 27 (2.8) 22 (3.6) .336 
ICH 65 (4.1) 36 (3.7) 28 (4.6) .882 
GIB 193 (12.2) 36 (3.7) 138 (22.7) .043 
Haematuria 291 (18.4) 181 (18.5) 110 (18.2) .976 
Any blood transfusion 646 (40.8) 471 (48.2) 193 (31.8) .247 
CHA2DS2‐VASc score  3.7 ± 1.6 3.7 ± 1.6 3.7 ± 1.5 .408 
HAS‐BLED score 2.0 ± 1.0 1.9 ± 1.0 2.1 ± 1.1 .070 
Concomitant treatment 
Diuretics 942 (59.5) 586 (60.0) 356 (58,79) .600 
ACE inhibitors 518 (32.7) 347 (35.5) 171 (28.2) .002 
ARB 624 (39.4) 349 (35.7) 275 (45.3) <.001 
Statins 869 (54.9) 531 (54.4) 338 (55.7) .604 
Antiplatelet agents 165 (10.4) 88 (9.0) 76 (12.5) .026 
Beta‐blockers 961 (60.7) 595 (60.9) 366 (60.3) .811 
Digoxin 303 (19.1) 192 (19.7) 111 (18.3) .502 
Baseline physical examination 
SBP (mm Hg) 132.7 ± 18.8 132.4 ± 19.4 133.1 ± 17.8 .572 
DBP (mm Hg) 75.6 ± 11.5 75.4 ± 11.8 75.9 ± 11.0 .311 
HR (beats per min) 72,4 ± 14,9 72,5 ± 15,0 72,3 ± 14,8 .795 
BMI (Kg/m2)  29.0 ± 4.9 29.0 ± 5.0 29.1 ± 4.8 .821 
LVEF (%) 58.3 ± 11.4 57.7 ± 11.8 59.3 ± 10.6 .045 
Haemoglobin (g/dL) 13.7 ± 1.7 13.7 ± 1.7 13.6 ± 1.8 .815 
eGFR (mL/min) 65.5 ± 22.9 63.1 ± 21.4 69.4 ± 24.7 <.001 
Cholesterol (mg/dL) 177.3 ± 38.9 177.5 ± 39.3 176.9 ± 38.2 .925 
Glycaemia (mg/dL) 108.8 ± 32.0 109.3 ± 33.2 107.8 ± 30.1 .386 
     
COPD, chronic obstructive pulmonary disease; PAD, peripheral artery disease; CAD, coronary artery disease; eGFR, 
estimated glomerular filtrated rate; ICH, intracranial haemorrhage; GIB, gastrointestinal bleeding; ICH, intracranial 
haemorrhage; ACE, angiotensin‐converting enzyme; ARB, angiotensin‐receptor blockers; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; HR, heart rate; BMI, body mass index; LVEF, left ventricular ejection fraction.  
CHA2DS2‐VASc = congestive heart failure or left ventricular dysfunction (1); hypertension (1), age ≥ 75 (2) or 65‐74 (1), 
diabetes mellitus (1), prior stroke/TIA or systemic embolism (2), vascular disease (peripheral artery disease, myocardial 
infarction and aortic plaque) (1), sex category (ie female sex) (1); HAS‐BLED = hypertension (1), abnormal renal and/or 
liver function (1), prior stroke (1), bleeding history or predisposition (1), labile INR (1), elderly (1), drugs or excess alcohol 
(1).  
Numeric values are expressed as median (±standard deviation) or number (percentage).  
3.2 Previous heart disease history 
Patients in the group controlled by GPs had more previous heart disease (53.2% vs 43.3%, 
P < .001), heart failure (32.9% vs 26.5%, P = .008), cardiomyopathy (15.2% vs 8.7%, P < .001) 
and left ventricular hypertrophy due to arterial hypertension (18.1% vs 13.7%, P = .020) as well as 
a higher percentage of cardiac resynchronisation therapy (5.0% vs 1.5%, P < .001) (Table S1). 
Types of AF were similar in both groups, but more electrical cardioversion (19.8% vs 14.7%, 
P = .010) and previous AF ablation procedure (5.2% vs 2.1%, P = .002), rhythm control (41.9% vs 
34.3%, P = .003) and follow‐up by cardiology (88.7% vs 86.3%, P = .002) were observed in the 
GP group.  
 
The general population had high thrombotic and haemorrhagic risk, with CHA2DS2‐VASc 
mean score of 3.72 ± 1.58 and mean HAS‐BLED of 2.01 ± 1.03, with no differences between 
groups.  
3.3 Quality of anticoagulation control in both groups 
In the overall population studied, the quality of anticoagulation estimated by TTR by the 
Rosendaal method was 61.5 ± 24.1%; 52.6% of the patients had a TTR <65% and 60% of the 
patients had a TTR <70% (Table 2). The TTR was significantly higher in the GPs group 
(63.0 ± 24.4% vs 59.2 ± 25.6%, P = .005) with a lower proportion of patients with a TTR <65% 
(49.7% vs 57.1%, P = .004) and TTR <70% (56.8% vs 62.7%, P = .021) in the group managed by 
GPs.  
Table 2. Anticoagulation control according to the specialist responsible of the anticoagulation control 
 
Total n = 1,584 General practitioner n = 977 Haematologist n = 607 P‐value 
     
TTR (direct method‐PINRR) 65.1 ± 24.1 65.9 ± 24.0 63.8 ± 24.3 .068 
TTR (Rosendaal) 61.5 ± 24.9 63.0 ± 24.4 59.2 ± 25.6 .005 
INR Variability 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 1.0 .279 
TTR < 65% 52.6 49.7 57.1 .004 
TTR < 70% 60.0 56.8 62.7 .021 
     
 
TTR, time in therapeutic range assessed by Rosendaal Method; INR, international normalised ratio; PINRR, percentage of 
international normalised range (INR) in therapeutic range.  
Numeric values are expressed as media (± standard deviation) or number (percentage).  
 
 
 
  
After the univariate and multivariate analysis, only the management of anticoagulation 
according to the type of specialist was independently associated with poor anticoagulation control 
(TTR <65%) with an OR 1.35 ([95% CI, 1‐1.7], P = .005). (Table 3). 
Table 3. Clinical factors related with poor anticoagulation control (TTR 65%) by univariate and multivariate regression 
analysis 
 
Univariate analysis OR (95% CI); P ‐value Multivariate analysis OR (95% CI); P‐value 
   
Age 1.0 (0.99‐1.01); .894 ‐ 
Male sex 1.11 (0.91‐1.36); .297 ‐ 
Hypertension 1.11 (0.86‐1.42); .422 ‐ 
Chronic kidney disease 1.29 (1.01‐1.64); .043 1.10 (0.83‐1.44); .513 
Previous heart disease 1.07 (0.88‐1.30); .514 ‐ 
Haematologist control 1.34 (1.10‐1.65); .004 1.35 (1.09‐1.66); .005 
Diabetes mellitus 1.39 (1.12‐1.73); .003 1.23 (0.94‐1.61); .124 
Charlson Index 1.14 (1.05‐1.24); .003 1.08 (0.96‐1.21); .203 
Previous bleeding 1.58 (0.87‐2.84); .131 1.26 (0.68‐2.31); .463 
CHADS2 score  1.11 (1.03‐1.21); .008 0.95 (0.78‐1.15); .587 
CHA2DS2‐VASc score  1.09 (1.02‐1.16); .007 1.03 (0.89‐1.19); .720 
HAS‐BLED score 1.18 (1.07‐1.30); .001 1.12 (0.98‐1.27); .095 
   
 
OR, odds ratio; CI, confidence interval. 
 
4. DISCUSSION 
The results of this ancillary study from the FANTASIIA Registry show that 60% AF patients 
had poor quality control with VKA therapy (ie TTR <70%), with a slightly better management of 
anticoagulation by GPs. Poor anticoagulation control was evident in patients with AF, although the 
management of anticoagulation by GPs was slightly better.  
 
Previous studies have shown that poor anticoagulation control is associated with a worse 
prognosis, increasing not only the risk of stroke and systemic embolism, but also increasing 
bleeding, ischaemic heart disease and mortality.
11, 19-22
 In clinical practice, the TTR levels are 
below than those reported in randomised trials where fewer confounding variables exist and strict 
criteria for patient selection prevail. The GARFIELD‐AF registry20 showed an increased risk of 
2.6 for thromboembolism, 1.5‐fold high risk for bleeding and all‐cause mortality of 2.5 with TTR 
<65%.  
 
Clinical guidelines recommend the evaluation of TTR using Rosendaal method and its use 
should alert healthcare practitioners to inadequate anticoagulation control. However, the use of this 
method in daily clinical practice is difficult and in this sense, the availability of instruments that 
facilitate the use of Rosendaal, perhaps incorporated automatically in the electronic history and 
elements such as electronic alerts, could be elements of improvement.  
 
This comparative analysis between two varying organisational models is reflected in the 
international literature but poorly established, at least as far as we know, in the current literature in 
our country, which describes results separately depending on GPs or haematologists. For this 
reason, the FANTASIIA Registry provides an ideal scenario to study this topic. In our series, 
patients with anticoagulation control by GPs represent greater than 50%. Mean age, percentage of 
women, type of AF, comorbidies, risk factors, stroke and previous major bleeding were similar in 
both populations, although in the haematologist‐controlled group, there was greater concomitant 
use of antiplatelet agents. In addition, patients in both groups were at high risk of both thrombotic 
and haemorrhagic events, similar to the GARFIELD‐AF registry data.20 Nevertheless, patients 
with anticoagulation control by GPs had significantly more concomitant cardiac and extracardiac 
pathology. Many patients in this group were clinically followed by cardiologists and consistent 
with the literature,
23, 24
 a strategy of control of rhythm control, cardioversion and previous ablation 
was decided in a greater proportion of patients in comparison with those in which the control of 
anticoagulation was performed by haematologists with less clinical follow‐up by cardiologists.  
 
Differences in TTR and quality of anticoagulation control have been reported previously 
between patients controlled by GPs with those controlled by haematologic clinics. In a meta‐
analysis by Baker et al,
25
 8 studies with more than 22 000 patients demonstrated a mean TTR of 
55%, being significantly lower when the control was carried out by GPs vs Hematology (63 vs 
51%). In our study, the mean TTR estimated by the Rosendaal method had higher values than in 
the American study. In contrast, mean TTR in our analysis was significantly higher in patients 
controlled by GPs than by haematologists. In addition, the higher propensity towards poorer 
control associated with being the haematologist responsible for control of anticoagulation was not 
modified when the analyses were adjusted for the variables associated with poor control of 
anticoagulation such as a high HAS‐BLED score or history of bleeding. It should be noted that we 
are not comparing professionals (haematologist vs primary care physicians) but two differing 
anticoagulation management systems (including number of visits, patient accessibility and 
availability of important clinical information). However, there are other models to assess the 
quality of anticoagulation. Hou et al26 performed a systematic review of 8 clinical trials and 9 
observational studies and observed that the risk of thromboembolic and bleeding events 
significantly decreased in patients where the anticoagulation management was based on 
pharmacist‐led management compared to the anticoagulation clinics or treatment with GPs. 
Conversely, many studies have reported improvements in the quality of oral anticoagulation with 
self‐testing and self‐management approaches, with possible improvements in clinical outcomes. 
Verret et al
27
 demonstrated that self‐management of anticoagulation in AF patients improved the 
quality of life with the same or higher quality of anticoagulation compared to the management in 
anticoagulation clinics. These results reflect different models focus on the importance of the 
patient as an active actor of the decision‐making process of anticoagulation therapy. In this way, it 
is mandatory to facilitate the access to the anticoagulation control. GPs generally are closer to AF 
patient's homes than anticoagulation clinics. Indeed, some studies reflect the efficacy of point‐of‐
care testing devices with CoaguChek
®
 to avoid wasting a lot of time performing blood sample test 
in the anticoagulation clinics.
28 
 
Nevertheless, in our study, the TTR levels reflected a poor quality of anticoagulation with 
VKAs, independent of the specialist in charge. These data contrast with the Swedish registry 
AuriculA
29
 that included more than 18 000 patients and showed a high rate of good quality of the 
anticoagulation and a mean TTR of 76%, and better still in primary care with TTR of 80% than in 
the haematology clinics with mean TTR of 76%. The authors argued that this difference could be 
because the population controlled by GPs could be healthier, with less comorbidity and difficulty 
in maintaining the INR in range. This is not the case in this present study, where the population 
controlled in primary care had a slightly better quality of anticoagulation although they had more 
previous heart disease, lower left ventricular ejection fraction and worse renal function. Most 
likely, the cause of this difference in our study is related to the different organisational systems.  
 
In any case, we observed a low TTR, independent of the anticoagulation management 
specialist. Also, several studies
19, 30-33
 showed that 40%‐54% of anticoagulated patients with VKAs 
in our country had a low quality of anticoagulation with a TTR of <65% estimated by Rosendaal. 
Additionally, the different organisational models of anticoagulation control should be aimed at 
improving quality. Centralised control, without direct patient review, has not been shown in our 
study to lead to improvement.  
  
The results of our analysis of the FANTASIIA registry, like the data from previous studies, 
show that there is wide room for improvement of anticoagulation control and prognosis of patients 
in daily clinical practice. This makes it necessary to optimize treatment with all available 
variables, such as the correct training of professionals, the homogenous management of AF by the 
different specialists involved, the training of patients and the accessibility of direct anticoagulants 
that have the same or better effectiveness than warfarin with better safety profile1 The design of 
the FANTASIIA Registry offers the possibility to know this improvement, with the further 
analysis planned for 1 year, two and 2 years of evolution.  
4.1 Limitations 
We are comparing two systems that differ not only in professionals involved but also in 
different variables of difficult weight such as number of visits and determinations, availability of 
relevant clinical information or hospital admissions, but we had available 12 values of the INRs of 
each patient. In this analysis, the number of patients included, the dispersion of the participants 
and the selection of the patients indicate that the information provided is a good approximation of 
the quality of AVK anticoagulation in Spain with different organisational systems.  
5. CONCLUSIONS 
In the FANTASIIA registry, about 60% of AF patients anticoagulated with VKAs had poor 
anticoagulation control and their management was only slightly better than when the management 
was performed by general practitioners. Overall, there is wide room for improvement in 
anticoagulation quality and it seems that anticoagulation control focused on primary care is only 
slightly better.  
CONFLICT OF INTEREST 
The authors have no conflict of interest to disclose. 
REFERENCES 
1. Kirchhof P, Benuss S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial 
fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893‐2962.  
2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the 
management of patients with atrial fibrillation: a report of the american college of 
cardiology/american heart association task force on practice guidelines and the heart 
rhythm society. Circulation. 2014;130:199‐267.  
3. Gómez‐Doblas JJ, Muñiz J, Alonso Martin JJ, et al. Prevalencia de fibrilación auricular en 
España. Resultados del estudio OFRECE. Rev Esp Cardiol. 2014;67:259‐269.  
4. Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke 
prevention in atrial fibrillation underestimated? Stroke. 2005;36:360‐365.  
5. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and 
congestive heart failure and their joint influence on mortality: the Framingham Heart 
Study. Circulation. 2003;107:2920‐2925.  
6. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, 
risk factors, and prognosis in the Manitoba Follow‐Up Study. Am J Med. 1995;98:476‐
484.  
7. Stewart S, Hart CL, Hole DJ, et al. A population‐based study of the long‐term risks 
associated with atrial fibrillation: 20‐year follow‐up of the Renfrew/Paisley study. Am J 
Med. 2002;113:359‐364.  
8. Kirchchof P, Ammentorp B, Darius H, De Caterina R, et al. Management of atrial 
fibrillation in seven European countries after the publication of the 2010 ESC Guidelines 
on atrial fibrillation: primary results of the PREFER in AF. Europace. 2014;16:6‐14.  
9. Lip GYH, Laroche C, Dan GA, et al. A prospective survey in European Society of 
Cardiology member countries of atrial fibrillation management: baseline results of EORP‐
AF Pilot General Registry. Europace. 2014;16:308‐319.  
10. Lip GYH, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation 
patients by european cardiologists: one year follow‐up of the EORP‐AF Pilot registry. Eur 
Heart J. 2014;35:3365‐3376.  
11. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet 
therapy in atrial fibrillation depends on the quality of International normalized ratio 
control achieved by centres and countries as measured by time in therapeutic range. 
Circulation. 2008;118:2029‐2037.  
12. Chan PH, Li WH, Hai JJ, et al. Time in therapeutic range and percentage of international 
normalized ratio in the therapeutic range as a measure of quality of anticoagulation 
control in patients with atrial fibrillation. Can J Cardiol. 2016;32:1247. e23–1247.e28.  
13. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the 
optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236‐239.  
14. Björck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Själander A. Outcomes in a 
Warfarin‐treated population with atrial fibrillation. JAMA Cardiol. 2016;1:172‐180.  
15. Sjögren V, Grzymala‐Lubanski B, Renlund H, et al. Safety and efficacy of well managed 
warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 
2015;113:1370‐1377.  
16. Roldán Rabadán I, Anguita Sánchez M, Marín F, et al. Tratamiento antiarrítmico actual 
de la fibrilación auricular no valvular en España. Datos del Registro FANTASIIA. Rev 
Esp Cardiol. 2016;69:54‐60.  
17. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines 
for health research. Eur J Clin Invest. 2010;40:35‐53.  
18. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic 
anticoagulation. A multicenter study. Warfarin optimized outpatient follow‐up study 
group. Ann Intern Med. 1993;118:511‐520.  
19. Bertomeu‐González V, Anguita M, Moreno‐Arribas J, et al. Quality of anticoagulation 
with vitamin K antagonists. Clin Cardiol. 2015;38:357‐364.  
20. Haas S, Ten Cate H, Accetta G, et al. Quality of vitamin K antagonist control and 1‐year 
outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD‐AF 
registry. PLoS ONE. 2016;11:e0164076.  
21. Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial 
fibrillation: observing outcomes associated with varying levels of INR control. Thromb 
Res. 2009;124:37‐41.  
22. Pastori D, Pignatelli P, Saliola M, et al. Inadequate anticoagulation by Vitamin K 
antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial 
fibrillation. Int J Cardiol. 2015;15:513‐516.  
23. Fosbol EL, Holmes DN, Piccini JP, et al. Provider specialty and atrial fibrillation 
treatment strategies in United States community practice: findings from the ORBIT‐AF 
registry. J Am Heart Assoc. 2013;2:e000110.  
24. Funk AM, Kocher KE, Rohde JM, et al. Variation in practice patterns among specialties 
in the acute Management of atrial fibrillation. BMC Cardiovasc Disord. 2015;15:21.  
25. Baker WL, Cios DA, Sander SD, Coleman CI. Meta‐analysis to assess the quality of 
warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 
2009;15:244‐252.  
26. Hou K, Yang H, Ye Z, Wang Y, Liu L, Cui X. Effectiveness of pharmacist‐led 
anticoagulation management on clinical outcomes: a systematic review and meta‐analysis. 
J Pharm Pharm Sci. 2017;20:378‐396.  
27. Verret L, Couturier J, Rozon A, et al. Impact of a pharmacist‐led warfarin self‐
management program on quality of life and anticoagulation control: a randomized trial. 
Pharmacotherapy. 2012;32:871‐879.  
28. Okuyama Y, Matsuo M, Matsuo H, et al. Introduction of point‐of‐care testing in Japanese 
outpatient clinics is associated with improvement in time in therapeutic range in 
anticoagulant‐treated patients. Circ J. 2014;78:1342‐1348.  
29. Wieloch M, Själander A, Frykman V, et al. Anticoagulation control in Sweden: reports of 
time in therapeutic range, major bleeding, and thrombo‐embolic complications from the 
national quality registry AuriculA. Eur Heart J. 2011;32:2282‐2289.  
30. Anguita M, Cequier A, Bertomeu V; e Investigadores del Estudio CALIFA. Mal control 
de la anticoagulación con antagonistas de la vitamina K en pacientes con fibrilación 
auricular no valvular en España: prevalencia actual y factores asociados. Rev Esp Cardiol 
2015; 68:761‐768.  
31. Barrios V, Escobar C, Prieto L, et al. Anticoagulation control in patients with nonvalvular 
atrial fibrillation attended at primary care centres in Spain: the PAULA Study. Rev Esp 
Cardiol. 2015;68:769‐776.  
32. Sinza‐Sanjurjo S, Rey‐Aldana D, Gestal‐Pereira E, Calvo‐Gómez C. Evaluación del grado 
de anticoagulación de pacientes con fibrilación auricular en el ámbito de atención 
primaria en Galicia. Estudio ANFAGAL. Rev Esp Cardiol. 2015;68:753‐760.  
33. Hugo GS, Figueiras‐Graillet LM, Anguita M, et al. Oral anticoagulation in octogenarians 
with atrial fibrillation. Int J Cardiol. 2016;223:87‐90. 
 
 
